Nishita Mayette
Family · Manchester, CTNPI 1588428973
Payments from drug & device makers
Across 121 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$653
- Johnson & Johnson$413
- Phathom Pharmaceuticals, Inc.$276
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$266
- Ardelyx, Inc.$241
- Gilead$136
- plus $565 from 9 others
What the payments were for
- Food & beverage$2,46597%
- Education$863%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $653 |
| Johnson & Johnson | 13 | $413 |
| Phathom Pharmaceuticals, Inc. | 17 | $276 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $266 |
| Ardelyx, Inc. | 10 | $241 |
| Gilead | 7 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $127 |
| Intercept Pharmaceuticals, Inc. | 3 | $78 |
| Madrigal Pharmaceuticals | 3 | $76 |
| QOL Medical, LLC | 2 | $74 |
| Braintree Laboratories, Inc. | 4 | $74 |
| Ironwood Pharmaceuticals, Inc | 3 | $62 |
| Exact Sciences | 1 | $34 |
| Novo Nordisk | 1 | $21 |
| Pfizer | 1 | $19 |
How this compares
$2,550 in reported general payments places this provider in the 85th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexlansoprazole DrDexlansoprazole | 14 | $3,852 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 52 | $2,827 |
| Sucralfate | 20 | $1,931 |
| Omeprazole | 122 | $1,771 |
| Famotidine | 71 | $1,292 |
| Pantoprazole Sodium | 70 | $873 |
| Esomeprazole Magnesium | 17 | $622 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 33 | $523 |
| Dicyclomine Hcl | 19 | $470 |
| Lansoprazole | 19 | $344 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 28 | $329 |
Paid to pharmacies, not to this prescriber.
Other family in Manchester
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
- Nicole SandilandsBridgeport$30K
- Ralph HirschfeldPutnam$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.